Oral Session

Oral Session 1-13B Conditioning Regimens (2)

Fri. Oct 11, 2019 10:10 AM - 11:10 AM No.13 (Tokyo International Forum, 6F G602)

Chair: Yasuharu Hamano (Department of Hematology, Juntendo University)

+Add all to schedule

[OS1-13B-1] PTCy ameliorates PD-1^-/- donor-induced GVHD by restoring regulatory and effector T cell homeostasis

Shuntaro Ikegawa, Kenichi Matsuoka, Yusuke Meguri, Takumi Kondo, Hiroyuki Sugiura, Yasuhisa Sando, Makoto Nakamura, Miki Iwamoto, Yoshinobu Maeda (Department of Hematology and Oncology, Okayama University, Okayama, Japan)

[OS1-13B-2] The impact of reduced dose of MMF on MAC based HLA-haploidentical PBSCT using PTCy

Junichi Sugita¹, Koji Nagafuji², Kazuteru Ohashi³, Miho Nara⁴, Nobuhiko Uoshima⁵, Shinya Kimura⁶, Keitaro Matsuo⁷, Koichi Akashi⁸, Shuichi Taniguchi⁹, Mine Harada¹⁰, Takanori Teshima¹ (1.Hematology, Hokkaido University Hospital, Sapporo, Japan, 2.Hematology and oncology, Kurume University Hospital, Kurume, Japan, 3.Hematology, Komagome Hospital, Tokyo, Japan, 4.Hematology, Akita University Hospital, Akita, Japan, 5.Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan, 6.Hematology and Oncology, Saga University Hospital, Saga, Japan, 7.Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan, 8.Hematology/Oncology, Kyushu University Hospital, Fukuoka, Japan, 9.Hematology, Toranomon Hospital, Tokyo, Japan, 10.Karatsu Higashimatsuura Medical Center, Karatsu, Japan)

[OS1-13B-3] Murine MHC-haploidentical transplant model using cyclophosphamide-resistant tumor cell lines

Isao Tawara¹, Komei Nishimura¹, Junya Tsuboi¹, Kazuko Ino¹, Yuki Kageyama¹, Kohshi Ohishi², Masahiro Masuya¹, Naoyuki Katayama¹ (1.Dept. Hematol., Mie Univ., Tsu, Japan, 2.Dept. Transfusion Med. & Cell Ther., Mie Univ., Tsu, Japan)

[OS1-13B-4] Impact of cytoreduction strategy and prognostic mutation on post-transplantation outcome in AML-MRC

Feng-Ming Tien^1,2, Cheng-Hong Tsai^1,2, Chien-Yuan Chen¹, Hsin-An Hou¹, Xiu-Wen Liao², Wen-Chien Chou¹, Hwei-Feng Tien¹, Jih-Luh Tang^1,2 (1.Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 2.TaiCheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan)

[OS1-13B-5] Retrospective comparison between fludarabine plus melphalan and fludarabine plus busulfan

Yuta Yamada, Yuho Najima, Hiroto Adachi, Atsushi Wada, Ryosuke Konuma, Yuya Kishida, Tatsuya Konishi, Akihito Nagata, Satoshi Kaito, Takuma Kumagai, Kota Yoshifuji, Junichi Mukae, Megumi Akiyama, Kyoko Inamoto, Takashi Toya, Aiko Igarashi, Takeshi Kobayashi, Kazuhiko Kakihana, Hisashi Sakamaki, Kazuteru Ohashi (Hematological Division, Komagome Hospital, Japan)

[OS1-13B-6] Conventional full-intensity conditioning allo-HSCT is worth considering in relatively older patients

Fumiaki Jinnouchi¹, Yuta Katayama¹, Ryota Imanaka¹, Tatsuya Terasaki¹, Takuya Nunomura¹, Takeshi Okatani¹, Kohei Kyo¹, Mitsuhiro Itagaki¹, Shinya Katsutani¹, Tsuyoshi Muta¹, Hideki Asaoku¹, Kozo Kashiwado², Koji Iwato¹ (1.Hematology Division, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, 2.Radiotherapy Division, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital)